Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (38740)	5/7/1999 12:52:00 PM
From: Joan Roth	Respond to of 120523

Thanks for checking on it.

To: Jenna who wrote (38740)	5/7/1999 1:02:00 PM
From: Jerry Olson	Read Replies (2) \| Respond to of 120523

CSCO is starting it's run......

To: Jenna who wrote (38740)	5/11/1999 4:49:00 PM
From: Jenna	Read Replies (1) \| Respond to of 120523

ENZN (+ 8.25%) reported this morning.. at least now we know Enzon Reports Third Quarter Fiscal Year 1999 Earnings techstocks.com PISCATAWAY, N.J.--(BUSINESS WIRE)--May 10, 1999--Enzon, Inc. (Nasdaq:ENZN - news) announced today a net loss of $1,441,000, or $0.04 per share, for the three months ended March 31, 1999, compared to a net loss of $1,727,000, or $0.06 per share, for the same period in fiscal year (FY) 1998. Sales of Enzon's FDA approved products ADAGEN(r) and ONCASPAR(r) increased by 21% to $3,136,000 for the three months ended March 31, 1999, as compared to $2,592,000 for the same period last year. Costs of sales, as a percentage of sales, increased to 42% for the three months ended March 31, 1999 as compared to 25% for the same period in 1998. The increase was primarily due to an increase in ONCASPAR production costs related to a previously disclosed manufacturing problem. Enzon has instituted temporary labeling and distribution modifications for ONCASPAR while the problem is being resolved.